Literature DB >> 22706088

Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection.

Jonathan P Moorman1, Jia M Wang, Ying Zhang, Xiao J Ji, Cheng J Ma, Xiao Y Wu, Zhan S Jia, Ke S Wang, Zhi Q Yao.   

Abstract

Hepatitis C virus (HCV) is remarkable at disrupting human immunity to establish chronic infection. Upregulation of inhibitory signaling pathways (such as T cell Ig and mucin domain protein-3 [Tim-3]) and accumulation of regulatory T cells (Tregs) play pivotal roles in suppressing antiviral effector T cell (Teff) responses that are essential for viral clearance. Although the Tim-3 pathway has been shown to negatively regulate Teffs, its role in regulating Foxp3(+) Tregs is poorly explored. In this study, we investigated whether and how the Tim-3 pathway alters Foxp3(+) Treg development and function in patients with chronic HCV infection. We found that Tim-3 was upregulated, not only on IL-2-producing CD4(+)CD25(+)Foxp3(-) Teffs, but also on CD4(+)CD25(+)Foxp3(+) Tregs, which accumulate in the peripheral blood of chronically HCV-infected individuals when compared with healthy subjects. Tim-3 expression on Foxp3(+) Tregs positively correlated with expression of the proliferation marker Ki67 on Tregs, but it was inversely associated with proliferation of IL-2-producing Teffs. Moreover, Foxp3(+) Tregs were found to be more resistant to, and Foxp3(-) Teffs more sensitive to, TCR activation-induced cell apoptosis, which was reversible by blocking Tim-3 signaling. Consistent with its role in T cell proliferation and apoptosis, blockade of Tim-3 on CD4(+)CD25(+) T cells promoted expansion of Teffs more substantially than Tregs through improving STAT-5 signaling, thus correcting the imbalance of Foxp3(+) Tregs/Foxp3(-) Teffs that was induced by HCV infection. Taken together, the Tim-3 pathway appears to control Treg and Teff balance through altering cell proliferation and apoptosis during HCV infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706088      PMCID: PMC3392408          DOI: 10.4049/jimmunol.1200162

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells.

Authors:  Jörn Bullwinkel; Bettina Baron-Lühr; Anja Lüdemann; Claudia Wohlenberg; Johannes Gerdes; Thomas Scholzen
Journal:  J Cell Physiol       Date:  2006-03       Impact factor: 6.384

2.  Foxp3-dependent programme of regulatory T-cell differentiation.

Authors:  Marc A Gavin; Jeffrey P Rasmussen; Jason D Fontenot; Valeria Vasta; Vincent C Manganiello; Joseph A Beavo; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-14       Impact factor: 49.962

3.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells.

Authors:  Pushpa Pandiyan; Lixin Zheng; Satoru Ishihara; Jennifer Reed; Michael J Lenardo
Journal:  Nat Immunol       Date:  2007-11-04       Impact factor: 25.606

Review 4.  Regulatory T cells and infection: a dangerous necessity.

Authors:  Yasmine Belkaid
Journal:  Nat Rev Immunol       Date:  2007-11       Impact factor: 53.106

5.  Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes.

Authors:  Ying Zhang; Cheng J Ma; Jia M Wang; Xiao J Ji; Xiao Y Wu; Jonathan P Moorman; Zhi Q Yao
Journal:  J Leukoc Biol       Date:  2011-08-15       Impact factor: 4.962

Review 6.  Global epidemiology of hepatitis C virus infection.

Authors:  Colin W Shepard; Lyn Finelli; Miriam J Alter
Journal:  Lancet Infect Dis       Date:  2005-09       Impact factor: 25.071

7.  Fas ligand is responsible for CXCR3 chemokine induction in CD4+ T cell-dependent liver damage.

Authors:  Michael W Cruise; John R Lukens; Aileen P Nguyen; Matthew G Lassen; Stephen N Waggoner; Young S Hahn
Journal:  J Immunol       Date:  2006-05-15       Impact factor: 5.422

8.  TGF-beta1 mRNA expression in liver biopsy specimens and TGF-beta1 serum levels in patients with chronic hepatitis C before and after antiviral therapy.

Authors:  B Marek; D Kajdaniuk; U Mazurek; E Janczewska-Kazek; B Kos-Kudla; B Strzalka; A Fila; D Niedziolka; M Beniowski; Z Ostrowska; H Borgiel-Marek; J Kajdaniuk; L Sieminska; M Nowak; T Wilczok; D Pakula; P Filipczyk
Journal:  J Clin Pharm Ther       Date:  2005-06       Impact factor: 2.512

9.  Differential regulation of SOCS-1 signalling in B and T lymphocytes by hepatitis C virus core protein.

Authors:  Zhi Qiang Yao; Deborah Prayther; Christopher Trabue; Zhi Ping Dong; Jonathan Moorman
Journal:  Immunology       Date:  2008-04-04       Impact factor: 7.397

10.  T cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1 signaling.

Authors:  Zhi Q Yao; Ellis King; Deborah Prayther; Deling Yin; Jonathan Moorman
Journal:  Viral Immunol       Date:  2007       Impact factor: 2.257

View more
  47 in total

1.  Soluble costimulatory molecule sTim3 regulates the differentiation of Th1 and Th2 in patients with unexplained recurrent spontaneous abortion.

Authors:  Mengru Wu; Yuejie Zhu; Jing Zhao; Haiquan Ai; Qiaoqiao Gong; Jia Zhang; Junda Zhao; Qingli Wang; Xiaoling La; Jianbing Ding
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Tim-3 is differently expressed in genetically susceptible C57BL/6 and resistant BALB/c mice during oral infection with Toxoplasma gondii.

Authors:  L C Berrocal Almanza; M Muñoz; A A Kühl; T Kamradt; M M Heimesaat; O Liesenfeld
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2013-09-23

3.  Protection of CD4+ T cells from hepatitis C virus infection-associated senescence via ΔNp63-miR-181a-Sirt1 pathway.

Authors:  Yun Zhou; Guang Y Li; Jun P Ren; Ling Wang; Juan Zhao; Shun B Ning; Ying Zhang; Jian Q Lian; Chang X Huang; Zhan S Jia; Jonathan P Moorman; Zhi Q Yao
Journal:  J Leukoc Biol       Date:  2016-06-27       Impact factor: 4.962

Review 4.  Role of Tim-3 in hepatitis B virus infection: An overview.

Authors:  Yuan Liu; Li-Fen Gao; Xiao-Hong Liang; Chun-Hong Ma
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

5.  Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Authors:  Roberto Ferrara; Laura Mezquita; Matthieu Texier; Jihene Lahmar; Clarisse Audigier-Valette; Laurent Tessonnier; Julien Mazieres; Gerard Zalcman; Solenn Brosseau; Sylvestre Le Moulec; Laura Leroy; Boris Duchemann; Corentin Lefebvre; Remi Veillon; Virginie Westeel; Serge Koscielny; Stephane Champiat; Charles Ferté; David Planchard; Jordi Remon; Marie-Eve Boucher; Anas Gazzah; Julien Adam; Emilio Bria; Giampaolo Tortora; Jean-Charles Soria; Benjamin Besse; Caroline Caramella
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

Review 6.  Immune checkpoint inhibitors for hepatocellular carcinoma.

Authors:  Christopher E Jensen; Arturo Loaiza-Bonilla; Paula A Bonilla-Reyes
Journal:  Hepat Oncol       Date:  2016-06-27

7.  Differential regulation of interleukin-12 (IL-12)/IL-23 by Tim-3 drives T(H)17 cell development during hepatitis C virus infection.

Authors:  Jia M Wang; Lei Shi; Cheng J Ma; Xiao J Ji; Ruo S Ying; Xiao Y Wu; Ke S Wang; Guangyu Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

8.  Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection.

Authors:  Jia M Wang; Cheng J Ma; Guang Y Li; Xiao Y Wu; Penny Thayer; Pamela Greer; Ashley M Smith; Kevin P High; Jonathan P Moorman; Zhi Q Yao
Journal:  Vaccine       Date:  2013-03-14       Impact factor: 3.641

9.  Taming dendritic cells with TIM-3: another immunosuppressive strategy used by tumors.

Authors:  Jaina Patel; Erica N Bozeman; Periasamy Selvaraj
Journal:  Immunotherapy       Date:  2012-12       Impact factor: 4.196

Review 10.  Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Authors:  Yun Zhou; Ying Zhang; Jonathan P Moorman; Zhi Q Yao; Zhan S Jia
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.